Georgia State University (GSU) researchers have just published new results showing that high levels of a certain biomarker is linked to poor prognosis in African-American patients with triple-negative breast cancer.
Researchers are concerned that the dire outcome of this group could indicate that high-risk, African-American breast cancer patients are not being identified as such using standard clinical prognostic tools and aren't being prescribed sufficiently aggressive treatment. Findings from the new study were published recently in Scientific Reports through an article entitled “Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer.”
Racial disparities in disease, particularly breast cancer, continue to pose a major challenge in healthcare. African-American breast cancer patients are more likely to suffer from a more aggressive course of the disease and higher mortality compared to other racial groups. In particular, African-American patients with triple-negative breast cancer have a dismal prognosis. Therefore, it's critical to find novel biomarkers that could identify differences in tumor biology between racial groups and serve as risk predictors to help alleviate health disparity in disease outcomes.
In the current study, the GSU team examined whether a biomarker called nuclear KIFC1, which has been associated with worse outcomes in breast cancer, can predict risk in triple-negative breast cancer, a subtype that disproportionately affects African-American women.
"We looked at the levels of nuclear KIFC1 in their tumors, and interestingly, we found that African-American women had slightly higher levels, but it was only within African-American patients that the levels mattered for their outcome," explained lead study investigator Angela Ogden, a doctoral candidate in Georgia State's biology department. "African-American women with high nuclear KIFC1 levels tended to do poorly, whereas in white women, it didn't matter if they had high or low levels. It had no effect on their outcomes."
The researchers assessed the nuclear KIFC1 biomarker in triple-negative breast cancer tissue samples from 163 African-American patients and 144 white patients who were treated between the years 2003–2008 at Grady Memorial and Emory University hospitals, 2005–2013 at Northside Hospital and 2001–2012 at Baylor Scott & White Medical Center. Race information in medical records was self-declared by patients.
The researchers further investigated why the biomarker only seems to matter in African-American patients by studying triple-negative breast tumor cells from African-American and white patients.
"We found that if we silence the KIFC1 gene, it had a greater impact on the migration of the African-American cells than it did on the white cells," Ogden noted. "It may be that for whatever reason, in African-American breast cancer tumors, KIFC1 helps the cells to migrate and spread to other parts of the body. And for reasons that we currently don't know, that's not the case in white tumors. Ultimately, it may even be that African-American patients could potentially be treated with a KIFC1 inhibitor to help prevent metastasis, but that's for future studies."
The study is multi-institutional, with tumor samples from breast cancer patients treated at four different hospitals; so the results can likely be generalized. To ensure certain factors didn't confound the results, the researchers adjusted for tumor stage, age at diagnosis, receipt of chemotherapy, and the hospital where patients received chemotherapy. They found nuclear KIFC1 had a significant effect on outcomes in African-American patients, even after adjusting for these factors.
"The approach of treating all patients the same, regardless of their racial or ethnic background may not be the best approach as genetic ancestry matters," Ogden stated. "There may be biomarkers and treatments that work better for people of a certain ancestry, race, or ethnicity, instead of a one-size-fits-all approach."